CellProthera selected for JETRO’s Japan Entry Acceleration Program

CellProthera, a clinical-stage company developing regenerative cell therapies for ischemic diseases, has announced its s...

November 3, 2026 | Tuesday | News
Crossing borders for cell-based care: what providers owe international travelers

By Vincent Caradec, Co-Founder and CEO, Healthi Life Somewhere, this week, someone is booking a flight in the hope that...

November 3, 2026 | Tuesday | Opinion
Singapore study highlights hidden recurrence risk in node-negative early breast cancer patients

A new Singapore study found that around one in six (16.7%) higher-risk patients with hormone receptor-positive (HR+), HE...

November 2, 2026 | Monday | News
SG Austria/Austrianova announces peer-reviewed publication on implanted Cell-in-a-Box encapsulated cells for sustained delivery of anti-ageing protein Klotho

SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...

October 30, 2026 | Friday | News
SG Austria/Austrianova announces peer-reviewed publication on implanted Cell-in-a-Box encapsulated cells for sustained delivery of anti-ageing protein Klotho

SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...

October 30, 2026 | Friday | News
Stem-Cell Therapies Are No Longer a Distant Promise — The Real Challenge Is Delivering Lasting Results

Regenerative medicine is entering a defining phase as stem-cell research moves beyond laboratory discoveries towards cli...

October 29, 2026 | Thursday | Analysis
HighTide presents preclinical HTD1801 findings in polycystic kidney disease

HighTide Therapeutics, Inc., an innovative biopharmaceutical company specializing in the development of multifunctional,...

October 26, 2026 | Monday | News
Shionogi and F2G report Phase 3 results for oral antifungal olorofim

Shionogi and F2G have reported detailed results from the global Phase 3 OASIS study evaluating investigational oral anti...

October 22, 2026 | Thursday | News
Australian National University gets Google funding worth $2.2 M to support cancer research

The Australian National University (ANU) has been selected as a recipient of the Google.org Impact Challenge: AI for Sci...

October 23, 2026 | Friday | News
EQT to Acquire QIAGEN in Landmark €10.8 Billion Take-Private Deal

QIAGEN and EQT Private Equity agree on an all-cash public takeover offer for all outstanding QIAGEN shares at an off...

October 22, 2026 | Thursday | News
BioNTech opens advanced mRNA manufacturing facility in Australia to accelerate next-generation therapies

La Trobe University is now home to one of the world’s leading biopharmaceutical companies, with the official ope...

October 21, 2026 | Wednesday | News
Merck expands rare disease portfolio with $1.3 billion Silence Therapeutics acquisition

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximat...

October 21, 2026 | Wednesday | News
HistoIndex partners with A*STAR to advance early-stage development of pipeline therapies for fibrotic diseases in Singapore

HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology ...

October 19, 2026 | Monday | News
AI drug discovery must deliver repeatable value beyond hype: Insilico Medicine’s Feng Ren

Artificial intelligence is changing how researchers identify therapeutic targets and design molecules, but its lasting v...

October 13, 2026 | Tuesday | Opinion
Everest Medicines announces NMPA acceptance of LEROCHOL BLA for hypercholesterolemia

Everest Medicines announced on June 26, 2026, that China’s National Medical Products Administration (NMPA) accepte...

October 12, 2026 | Monday | News
Andelyn Biosciences and PQP Group partner to streamline EU and UK supply pathways for cell and gene therapies

Andelyn Biosciences (“Andelyn”), a leading US-based patient-focused cell and gene therapy Contract Developme...

October 8, 2026 | Thursday | News
Vitalant launches cell-based analytics lab to support allogeneic therapy developers

Vitalant, one of the nation’s largest nonprofit blood and biotherapies healthcare organisations, has announced the...

October 6, 2026 | Tuesday | News
Independent CGT manufacturers launch global alliance to support therapy scale-up

Cell and gene therapies may now be moving faster than the manufacturing networks built to deliver them. The Alliance of...

October 6, 2026 | Tuesday | News
Germfree launches biopharmaceutical isolator for cell and gene therapy workflows

Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences,...

October 6, 2026 | Tuesday | News
Terumo BCT partners TrAMPoline Pharma to automate TIL therapy manufacturing

Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies ...

October 6, 2026 | Tuesday | News
AABB expands biotherapies coverage with special TRANSFUSION journal supplement

The Association for the Advancement of Blood & Biotherapies (AABB) has published a special supplemental issue of its...

October 1, 2026 | Thursday | News
European Commission grants marketing authorisation for NEZGLYAL, first pharmacological treatment for cALD

Neuraxpharm Group and Minoryx Therapeutics have announced that the European Commission has granted marketing authorisati...

September 28, 2026 | Monday | News
APEC’s Opportunity to Lead: Transforming Lung Cancer Outcomes Across Asia Pacific

As Asia Pacific economies grapple with ageing populations, shrinking workforces and rising healthcare expenditure, they ...

September 28, 2026 | Monday | News
IASO Bio receives FDA IND clearance for CD20-targeted in vivo CAR-T therapy

IASO Biotechnology has received US Food and Drug Administration clearance for the Investigational New Drug application o...

September 18, 2026 | Friday | News
Accro and Fosun advance oral TYK2/JAK1 inhibitor AC-201 into China Phase II/III vitiligo trial

Accro Bioscience and Fosun Pharma are preparing to advance AC-201 into a Phase II/III clinical trial in China for non-se...

September 9, 2026 | Wednesday | News